Health Economics for Non-Health-Economists

By attending this course, you will:

	1	Learn about the language, key principles and methods of health economic evaluations.
	2	Know how to interpret the results of health economic evaluations.
	3	Learn to integrate health economic evaluations in product development, pre-marketing and post launch.
	4	Gain insight into the perspective of decision makers.
	5	Ensure alignment of health economics with marketing strategies.
	6	Understand and avoid the pitfalls of health economic evaluations.
	7	Gain expert insight and advice from Lieven Annemans who conducted health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas.

 

What sets the Health Economics for Non-Health-Economists course apart?

The expert: Our expert-trainer, Prof. Lieven Annemans, not only has a wide international experience in health economic evaluations (over 200 completed projects with over 30 different pharmaceutical or medical device companies) but also built a very strong reputation within the international pharmaco-economic community as a high-impact trainer. Throughout his career, Lieven has worked in pharmaceutical companies, in health care policy environments, in consultancy and in academic positions.

The content: This course not only provides you with an explanation of concepts and methods. More importantly, it discusses the integration of health economic evaluation in clinical development and brand marketing plans (with practical examples), as well as the perspective of the decision maker, including examples of successful applications of health economic evaluations.

Who should attend?

As the course title suggests, this course is designed for non-health-economists.

As pharma companies are facing ever-increasing hurdles to optimize market access for their brands, all managers in product development and marketing should attend such course so that they can contribute to a successful integration of health economic evaluations into clinical and brand plans.

Past participants

Below is a non-exhaustive list of executives who participated in the Health Economics for Non-Health-Economists course:

Scientific Affairs Manager	Abbott	Germany	testimonial
Business Unit Director	AbbVie	Czech Republic & Slovakia	testimonial
Medical and Health Outcome Advisor	Baxter	The Netherlands	testimonial
Health Economics Specialist	Bayer	Turkey	testimonial
Pricing Manager	Bayer Schering Pharma	Germany	testimonial
Global Teamleader, Marketing Pipeline Products	Boehringer Ingelheim	Germany	testimonial
Head of RCV - Emerging Market Russia	Boehringer Ingelheim	Austria	testimonial
Pricing Manager	Boehringer Ingelheim	UK	testimonial
Regional Operations Manager	Boehringer Ingelheim	UK	testimonial
Market Access and Public Affairs Director	Bristol-Myers Squibb	Portugal	testimonial
Pricing & Health Economics Manager	Bristol-Myers Squibb	Romania	testimonial
Country Manager	Celgene	Belgium
Disease Area Access Lead, Europe	BMS	UK	testimonial
Commercial Operations Vice President	Daiichi Sankyo	Germany
Sales & Product Manager	Ferring	Denmark	testimonial
Regulatory Affairs & QA Mgr	Genzyme	Belgium	testimonial
Executive Director Market Access	Grünenthal	Germany
Health Economics & Outcomes Research Coordinator	GSK	Turkiye
Senior Director	Janssen	Belgium	testimonial
VP Licensing & New Business Development EMEA	Janssen Pharmaceutica	Belgium
Director Government Affairs EMEA	J&J	Belgium	testimonial
Market Access Manager	LEO Pharma	Portugal	testimonial
Global Project Leader	Merck Serono	Switzerland	testimonial
Health Economics Manager	MSD	The Netherlands
Clinical Trial Officer	Mundipharma	The Netherlands
Medical Officer	Mundipharma	Belgium	testimonial
Head BF IDTI & Ophthalmics	Novartis	The Netherlands	testimonial
Medical Scientific Liaison	Novartis	The Netherlands	testimonial
Sales Effectiveness Manager - International Operations	Novo Nordisk	Switzerland	testimonial
Health Economics & Market Access Manager	Nutricia	The Netherlands	testimonial
Development Leader	Orion Pharma	Finland	testimonial
European Director	Pfizer	UK
Senior Scientific Adviser	Pfizer	UK	testimonial
Program Manager	Roche Diagnostics	Switzerland	testimonial
In-Market Pricing Manager	Roche	Switzerland	testimonial
Strategic Planning & Market Access Manager	Sanofi	Romania	testimonial
Sales Force Excellence & Business Process Manager	Sanofi-aventis	Denmark
Commercial Director	Sanofi-aventis	Ukraine	testimonial
Medical Affairs Manager	Sanofi Pasteur MSD	The Netherlands	testimonial
Senior Director, Global Medical Affairs	Sanofi Pasteur	France	testimonial
Head Anesthesia & Analgesia - Global Clinical Research	Schering Plough	The Netherlands	testimonial
Market Access Officer	Servier	Romania	testimonial
Industrial Pharmacist	SMB	Belgium	testimonial
Head of Global Regulatory	Solvay	Germany
European Marketing Manager	Takeda	UK	testimonial
European Marketing Manager, Established Brands	Takeda	UK	testimonial
Medical Scientist	The Medicines Company	Italy	testimonial
Medical Writer	Trial Form Support	Denmark	testimonial
Pharmacovigilance & Clinical Trial Manager	Vianex	Greece	testimonial

Programme outline of the Health Economics for Non-Health-Economists course

The course starts on day 1 at 09:30h with a welcome coffee and ends on day 2 at 16:30h.

Day 1

Welcome & General Introduction

Health Economic Evaluations: Why - What - How Why health economic evaluations Why health economic evaluations receive increasing attention in marketing messages Key definitions & terminology: talking the same language From value proposition to cost-effectiveness Main methods of health economic evaluations Exercise on QALYs

Health Economic Modelling – Commonly Used Models Back of the envelope models Simple decision trees (+ examples) Markov models (+ examples) Exercise on decision tree model

Issues in Analysing Costs and Savings The perspective of the study (e.g. building in absenteeism in the value message?) The study setting: hospital-based drugs and ambulatory drugs require different approaches! How to deal with current benefits versus benefits in the far future? Budget impact implications: state-of-the-art Exercise on budget impact

Guidelines for the Conduct and Reporting of Health Economic Evaluation What distinguishes a good from a bad health economic evaluation? What can one do to increase the credibility of health economic messages in the value message? A 10-item checklist for a good health economic paper Exercise on guidelines: how to distinguish a good health economic paper from a poor quality paper.

GROUP DINNER Day 2

Prospective Health Economic Evaluations Aligning health economic data with clinical data Conflicts of interest between the clinical and the health economic perspective Practical steps for prospective health economic studies

Use of Health Economic Evaluations in Different Countries The large differences in payer expectations Methodological challenges: from very simple messages to high tech requirements Pitfalls of health economic evaluations: why some messages fail to have an impact Exercise on priority setting

Health Economic Evaluation in a Pharmaceutical Drug's Life Cycle Pre-marketing Developing a value dossier Organisation and process within HQ and affiliates Where to get the data? The cost-effectiveness of cost-effectiveness studies Post-launch How to prepare for a second assessment

Final Exercise: Developing an inventory of information needs for a typical health economic dossier.

Final Discussion and Close

Learning methodology

Prof. Lieven Annemans is very experienced in leading interactive sessions and will actively engage participants in discussions. In addition, two exercises will be used to help bringing theory into practice.

Meet the expert: Prof. Dr. Lieven Annemans

Lieven Annemans is a Full Professor of Health Economics at Ghent University and Brussels University. He is Past-President of ISPOR, the International Society for PharmacoEconomics and Outcomes Research, chairman of the Flemish Health Council (advising the Minister of Health), and external expert to the Belgian HTA body “KCE”. He has experience in health economic evaluations of pharmaceutical drugs, medical devices and preventive health actions in various medical areas, and conducted studies in over 20 countries. He is currently also active as an independent consultant in health economics and prior to his professorship he has also worked in the pharma industry.

His main interests are epidemiological models, early new technology assessment, retrospective/ prospective health economic evaluations, and physician payment systems. He has published over 100 papers in peer-reviewed journals, presented over 250 posters/papers at conferences and has given over 300 lectures and trainings on health economic evaluation. He is the author of the book “Health economics for non-economists: an introduction to the principles, methods and pitfalls of health economic evaluations” (info@academiapress.be).

Dates

• 28-29 May 2013, London
• 24-25 September 2013, Brussels
• 11-12 December 2013, Brussels

Interested in additional dates?
Leave your email address to be kept informed:

Venue & Accommodation

28-29 May 2013, London

This course takes place at the Sofitel London Heathrow Hotel which has direct access to Terminal 5 via a covered walkway and Terminals 1, 2, 3  and Terminal 4 via courtesy Heathrow Express and connect rail connection. The hotel is only 21 minutes from Central London by train.

Sofitel London Heathrow Hotel
Terminal 5
London Heathrow Airport
TW6 2GD London
United Kingdom
Tel: +44 20 87 57 77 77
Fax: +44 20 87 57 77 88

We have secured preferential room rates at this hotel for our delegates. Registering three weeks or more prior to the course will secure your room at a preferential rate. Upon your registration, C.E.L.forpharma will send you a Hotel Accommodation Sheet to complete and send back.
Do not hesitate to contact Marie Stricklesse, Senior Programme Coordinator, if you need assistance in this matter. (marie.stricklesse@celforpharma.com; tel +32(0)27092241)

24-25 September 2013, Brussels
11-12 December 2013, Brussels

These courses take place at the Sheraton Airport Hotel & Conference Center which is situated opposite Brussels National Airport, literally at 2 minutes' walking distance from the arrival hall.

Sheraton Brussels Airport Hotel
Brussels National Airport
1930 Zaventem
Belgium
Tel: +32 27 10 80 00
Fax: +32 27 10 80 80

We have secured preferential room rates at this four-star hotel for our delegates. Registering three weeks or more prior to the course will secure your room at a preferential rate. Upon your registration, C.E.L.forpharma will send you a Sheraton Brussels Airport Hotel Accommodation Sheet to complete and send back.
Do not hesitate to contact Marie Stricklesse, Senior Programme Coordinator, if you need assistance in this matter. (marie.stricklesse@celforpharma.com; tel +32(0)27092241)

Registration fee

28-29 May 2013 Course, London (HEC-13)		Price(*)
Registration after 12 April 2013		€3.370

24-25 Sep. 2013 Course, Brussels (HEC-14)		Price(*)
Registration before 9 August 2013		€2.970
Registration after 9 August 2013		€3.370

11-12 Dec. 2013 Course, Brussels (HEC-15)		Price(*)
Registration before 25 October 2013		€2.970
Registration after 25 October 2013		€3.370

* (VAT excl.)

To register, please go to our online registration form.

Testimonials of Health Economics for Non-Health-Economists

"It was an excellent course, very well organized and Prof. Dr. Lieven is by far the best teacher ever! Highly experienced, but truly accessible! I really enjoyed the course, it was very useful!"

Rita Marques, Market Access Manager, LEO Pharma – Portugal (February 2013)

"Just the right balance of theory and real-life examples to help non-health-economists ask the right questions."

Derek Brown, Global Teamleader, Marketing Pipeline Products, Boehringer Ingelheim – Germany (February 2013)

"Very good course done by a true expert in the field! Lieven is able to give a business-oriented overview of the pharmaco-economics field and challenges in a way that is understandable to non-specialists."

Eric Desauziers, Senior Director, Global Medical Affairs, Sanofi Pasteur - France (February 2013)

"A very clear introduction to health economic evaluations given by a charismatic speaker. Top!"

Emilie Beghin, Regulatory Affairs & QA Mgr, Genzyme - Belgium (February 2013)

"Very interesting course, presented in an animated way, with lots of items covered in a short time frame."

Elke Vandeputte, Medical Officer, Mundipharma - Belgium (February 2013)

"I have finally got a systematic and complete overview of HE."

Bibiana Soltysova, Business Unit Director, AbbVie, Czech Republic & Slovakia (February 2013)

"An excellent two days which delivered on its objectives! An exhaustive insight into HE, tailored appropriately to improve understanding."

Neil Edwards, Regional Operations Manager, Boehringer Ingelheim – UK (December 2012)

"Lieven is a nice and funny presenter. He appreciates different backgrounds and respects opinions. He makes bridges and is able to give practical tips and tricks."

Jolanda Koenders, Medical Scientific Liaison, Novartis – The Netherlands (December 2012)

"Health economics concepts presented and discussed by Lieven are even more exciting! Very refreshing and actual course."

Helena Freita, Market Access and Public Affairs Director, Bristol-Myers Squibb – Portugal (December 2012)

"Lieven was a very engaging and clear presenter and the two days went very well. Marie also did a fantastic job in keeping the training on track over the 2 days!!"

Debo Aremu, Pricing Manager, Boehringer Ingelheim – UK (December 2012)

"One of the most explicit and comprehensive courses in Health Economics on the market."

Dorian Costescu, Market Access Officer, Servier – Romania (September 2012)

"First class from the start to the very last minute. I will recommend to all people who engage with payers."

Jamie Rice, Regional Operations Manager, Boehringer Ingelheim – UK (September 2012)

"Lieven Annemans is a true expert and is able to explain the materials / themes extremely well. What I especially appreciate is that theories are always accompanied with real life examples. Lieven understands and knows the pharma industry very well."

Saskia De Haes, Senior Director, Janssen – Belgium (September 2012)

"I would recommend this course especially to my colleagues from the medical department so that they would understand the importance of clear end points for HE studies."

Burak Marmarali, Health Economics Specialist, Bayer – Turkey (June 2012)

"This course opened my eyes to the basics of health economics in a fun and educational way! Very valuable and interesting!"

Anna Trisia Beby, Medical and Health Outcome Advisor, Baxter – The Netherlands (June 2012)

"Lieven Annemans is a great expert, with humor, open to all questions and who explained the basic concepts of health economics very clearly!"

Maryvonnic Abeels, Industrial Pharmacist, SMB – Belgium (June 2012)

"Very valuable course to acquire quickly arguments to bring more early HTA into development."

Isabelle Lugan, Global Project Leader, Merck Serono – Switzerland (June 2012)

"Very inspiring speaker. Lieven explains the topic thoroughly and in a 'Layman' language."

Kati Kaijasilta, Development Leader, Orion Pharma – Finland (March 2012)

"Excellent overview for non-health-economists. Great teacher!"

Zenia Storling, Medical Writer, Trial Form Support – Denmark (March 2012)

"This course is highly recommended to all the persons involved in every development stage of a product and all the persons in direct negotiations with the payors."

Nadia Gorduza, Strategic Planning & Market Access Manager, Sanofi - Romania (December 2011)

“Lieven leads the group expertly, building up their knowledge, taking them on a journey, testing and challenging at appropriate times through questions and exercises. Thank you Lieven!”

Avi Leaf, European Marketing Manager, Takeda - UK (November 2011)   

“A great introduction to the dark art of health economics.”

Stephen Hogan, Director Government Affairs EMEA, J&J – Belgium (November 2011)

“Appropriate time spent on each topic with international issues as well as individual country issues covered. Perfect level for non-health economist pharma employees.”

Trine Ann Behnk, Sales & Product Manager, Ferring - Denmark (November 2011)

“Very helpful training! Very well delivered!”

Diana Omer, Pricing & Health Economics Manager, Bristol-Myers Squibb - Romania (November 2011)

“This was a highly interesting and engaging course on health economics. The only thing which would have added value would have been time to network and do exercises to understand the implementation of the theory. Great. Loved it.”

Julie Gaughan, Business Partnership Team Manager, Boehringer Ingelheim - UK (November 2011)

“Clear content, well organized, useful discussions.”

Achilleas Kalogirou, Pharmacovigilance & Clinical Trial Manager, Vianex – Greece (November 2011)

"Very good course to learn efficiently about principles of health economics, applications and advantages, but also about limitations in development submission and reimbursement."

Lieselotte Lennartz, Scientific Affairs Manager, Abbott – Germany (May 2011)

"Excellent course, very well delivered - I have learnt a lot. Thank you."

David Maddocks, Disease Area Access Lead, Europe, Bristol-Myers Squibb – UK (May 2011)

"Very well organised and friendly atmosphere. Lieven is a very experienced teacher but also, despite his wealth of knowledge, able to break down the complex theory in clear parts!"

John Rietveld, Head BF IDTI & Ophthalmics, Novartis - The Netherlands (May 2011)

"Invaluable course for any European marketer who needs to develop his understanding of the complex world of health economics. The course leader breaks through the jargon and brings the concepts to life in a relevant and memorable way."

Lisa Williams, European Marketing Manager, Established Brands, Takeda - UK

"I very much appreciated this valuable and practical health economics course, focused on real life cases/examples."

Peter Markotan, Head of RCV - Emerging Market Russia, Boehringer Ingelheim – Austria

"Lieven Annemans is very good in presenting the materials. He is an expert in the field with a lot of practical experience. The group is really good, there are lots of interesting exchanges, and the organisation of the event is on top level. Thank you!"

Oksana Vasiutynska, Commercial Director, Sanofi-aventis – Ukraine

“Lieven has the unique talent and ability to easily break down highly complex subjects and equip the audience with real and tangible tools. He also provides an understanding of the health economics arena. My only regret is not having attended this workshop earlier, as we all need this set of skills to work within the ever changing pharma environment. Well done, this was time well spent.”

Colin Hurworth, Sales Effectiveness Manager - International Operations, Novo Nordisk - Switzerland

“Adequate content, hands-on and up to date. Just right.”

Frank Junker, Program Manager, Roche Diagnostics - Switzerland

“Prof. Dr. Lieven Annemans is great! Enthusiastic and very knowledgeable.”

Gerben Hagenaars, Manager Healthcare Policy, Sanofi-aventis – The Netherlands

“A very useful course making a difficult subject very understandable. Pleasant atmosphere and good presentation skills with a sense of humor. I would advise this to anyone who needs more understanding of the subject!”

Bas Slierendregt, Medical Affairs Manager, Sanofi Pasteur MSD - The Netherlands

“Excellent faculty (Prof. Annemans) and good setting (small group of professionals), thus providing true value. Good mix of theory and practical applications”

Daniel Zollinger, Head Anesthesia & Analgesia - Global Clinical Research, Schering-Plough - The Netherlands

“The health economics workshop was a great introduction to this important area of market access. Now I have the confidence to integrate health economics in the product life cycle plan.”

Manjit Affley, Senior Scientific Adviser, Pfizer – UK

“Great, Lieven, well done! You are a very good communicator with a deep knowledge of the HECON.”

Bruno Bolognese, Medical Scientist, The Medicines Company – Italy

“My investment into the course of Lieven Annemans was cost-effective as the gain of quality is guaranteed in all aspects, in both theoretical and practical insights.”

Zuzana Melekova, In-Market Pricing Manager, Roche – Switzerland

“Great course with a lot of information and clear explanation in every aspect. Every question gets a clear and useful answer. In addition, you get a lot of information in the form of ppt slides that you can use to inform your own colleagues.“

Karen Freyer, Health Economics & Market Access Manager, Nutricia – The Netherlands

“Having a “pricing background” I am so pleased I learned the basics of HE, which is what I need to have a common ground for talking in the same “language” with my HE colleagues. Thanks for this comprehensive, intense training.”

Constanze Trautschold, Pricing Manager, Bayer Schering Pharma – Germany

Tips & Insights from Lieven Annemans:

• Can authorities continue to invest in healthcare while cutting budgets?
• The Budget Impact Analysis: an often overlooked dimension when trying to convince payers!
• Do you know how health economic evaluations are used in reimbursement decisions?

(Go to top of the Health Economics for Non-Health-Economists course page)